Pterostilbene for Health & Longevity

Evidence Review created on 08/04/2026 using AI4L / Opus 4.8

Also known as: trans-Pterostilbene, 3,5-Dimethoxy-4′-hydroxystilbene, Dimethylresveratrol, pTeroPure

Motivation

Pterostilbene (a natural relative of resveratrol) is a plant compound found most abundantly in blueberries, grapes, and the heartwood of the Indian Kino tree. It belongs to the same family as resveratrol but carries two small chemical modifications that let the body absorb far more of it and keep it in circulation longer. That improved uptake is the central reason interest has shifted toward pterostilbene among people who experiment with resveratrol-style compounds for healthy aging.

For centuries the plants that contain it were used in traditional medicine for blood-sugar and inflammatory complaints, long before the molecule itself was identified. Modern attention grew when laboratory work suggested it switches on some of the same cellular housekeeping and repair processes that fasting and calorie restriction trigger. It is now sold on its own and paired with a vitamin-based cellular-energy booster in popular longevity supplements.

This review examines what is actually known about pterostilbene: how it works in the body, which benefits and risks have human evidence behind them, how it is typically dosed, and where the science remains preliminary. The aim is to separate well-supported findings from claims that rest mainly on cell and animal studies.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Pterostilbene - Grokipedia

A comprehensive, referenced article covering pterostilbene’s chemistry, ~80% oral bioavailability versus resveratrol’s ~20%, biological activities, and research status. Useful as a structured technical starting point that links out to related compounds.

Examine

Pterostilbene - Examine

Examine’s evidence-graded supplement page compiles the human and animal research on pterostilbene, its dosing, and its safety signals in a neutral, study-by-study format. It is a good reference for cross-checking specific claims against the underlying trials.

ConsumerLab

No dedicated ConsumerLab article for pterostilbene was found. ConsumerLab has not published a standalone review or independent quality-testing report for pterostilbene as of the creation date.

Systematic Reviews

The pooled-evidence literature specific to pterostilbene is very limited; the single qualifying meta-analysis aggregates preclinical (animal) oxidative-damage studies rather than human trials.

The effect of pterostilbene and its active ingredients on experimental pulmonary fibrosis in asthma: a meta-analysis - Peng et al., 2022

A meta-analysis of seven randomized controlled animal experiments (62 animals total) finding that pterostilbene raised the antioxidant enzymes superoxide dismutase (SOD, an enzyme that neutralizes reactive oxygen species) and glutathione (GSH, the body’s main internal antioxidant) and lowered malondialdehyde (MDA, a marker of oxidative damage) across pulmonary fibrosis, diabetes, and myocardial infarction (heart attack) models. Because it pools only animal data with high statistical heterogeneity, it supports mechanism but not clinical efficacy.

Mechanism of Action

Pterostilbene is a dimethylated stilbene (a small two-ring plant molecule) closely related to resveratrol. Replacing two of resveratrol’s hydroxyl groups with methoxy groups makes the molecule more fat-soluble, which is why the body absorbs it far more efficiently.

Its main proposed actions are:

Sirtuin and energy-sensor activation: Pterostilbene is reported to activate SIRT1 (a repair-and-longevity enzyme that depends on NAD+) and AMPK (an enzyme that senses low cellular energy and switches on fat-burning and cellular clean-up). Together these are thought to shift cells toward a “maintenance” state resembling calorie restriction, and to dial down mTOR (a growth-signaling pathway whose suppression is linked to longevity).
Antioxidant defense: It activates Nrf2 (a master switch that turns on the cell’s built-in antioxidant genes), raising internal antioxidants such as glutathione and superoxide dismutase and lowering reactive oxygen species (ROS, unstable molecules that damage cells).
Anti-inflammatory signaling: It inhibits NF-κB (a control protein that drives inflammatory gene expression), lowering inflammatory messengers such as interleukin-1β and tumor necrosis factor-α.
Metabolic signaling: It engages PPARα (a receptor that regulates fat metabolism), which underlies some of its effects on cholesterol and blood sugar.

Where mechanisms are contested: the direct-versus-indirect activation of SIRT1 by stilbenes is debated, with critics arguing that apparent activation is partly an assay artifact and that AMPK activation may be the more relevant upstream event. Both interpretations remain in the literature.

Key pharmacological properties: pterostilbene has an oral bioavailability of roughly 80% in animal models (versus ~20% for resveratrol), driven by its methoxy groups. It has a relatively short elimination half-life (on the order of 1–2 hours), broad tissue distribution owing to its lipophilicity, and is cleared mainly by phase II conjugation — glucuronidation and sulfation via UGT (uridine glucuronosyltransferase) and SULT (sulfotransferase) enzymes — with comparatively little cytochrome P450 (CYP, a family of drug-metabolizing liver enzymes) involvement compared with resveratrol.

Historical Context & Evolution

Original context: The plants richest in pterostilbene — notably Pterocarpus marsupium (Indian Kino) heartwood — were used in traditional Ayurvedic medicine for diabetes and inflammatory conditions long before the specific molecule was characterized. Pterostilbene was first isolated in the mid-20th century as a plant phytoalexin (a natural antimicrobial compound plants make to defend themselves).
Why it came to longevity attention: Interest surged in the 2000s alongside the resveratrol-and-sirtuins hypothesis of aging. Researchers looking for a better-absorbed alternative to resveratrol found that pterostilbene reproduced many of the same effects in cell and rodent models — favorably influencing genes tied to cancer, metabolism, and inflammation — while overcoming resveratrol’s notoriously poor bioavailability.
Findings, not just reception: Early animal work reported reductions in blood lipids and blood glucose, antioxidant effects, and lifespan extension in fruit flies. A small number of human trials followed, testing pterostilbene alone for cardiometabolic markers and, more commonly, in combination with nicotinamide riboside for NAD+ restoration.
Evolution of opinion: The broader sirtuin-activator field has cooled from its initial hype as several direct-activation claims were challenged and human outcomes proved modest. Rather than being settled in either direction, the current picture is that pterostilbene has robust preclinical signals, promising but limited human data, and unresolved questions about how much its animal-model benefits translate.

Expected Benefits

Content below is framed for a proactive, risk-aware adult optimizing long-term health, not for treating diagnosed disease in the general population. Evidence grades reflect the strength of human data specific to pterostilbene.

Medium 🟩 🟩

Blood Pressure Reduction

In the best-controlled human trial to date, pterostilbene taken by mouth lowered both systolic and diastolic blood pressure, an effect consistent with its activation of energy-sensing and vascular-relaxation pathways. The evidence basis is a single randomized controlled trial (RCT, the most rigorous study design) of 80 adults with elevated cholesterol; the effect was clearest at the higher daily dose. Because it rests on one modest trial, it is graded Medium rather than High, and the blood-pressure benefit was accompanied by an unfavorable cholesterol signal (see Risks).

Magnitude: Roughly a 7–8 mmHg drop in systolic and a similar drop in diastolic blood pressure at 250 mg/day over 6–8 weeks (single RCT, n = 80).

Reduction of Oxidative Stress and Inflammation

Pterostilbene consistently activates the Nrf2 antioxidant switch and suppresses NF-κB-driven inflammation, raising internal antioxidants and lowering markers of oxidative damage. The evidence basis spans a meta-analysis of animal studies plus small human pilot work showing shifts in relevant biomarkers; the human data are preliminary and use surrogate markers rather than clinical outcomes. This is a plausible, mechanistically well-supported benefit that has not yet been tied to hard endpoints in people.

Magnitude: Not quantified in available studies.

Low 🟩

Metabolic and Liver Support (with Nicotinamide Riboside) ⚠️ Conflicted

When combined with nicotinamide riboside as a fixed formulation, pterostilbene has been studied for liver and metabolic health, with one trial reporting reduced liver-enzyme markers of inflammation in fatty liver disease. The evidence basis is a 6-month RCT in adults with non-alcoholic fatty liver disease (NAFLD, fat accumulation in the liver not caused by alcohol): the combination lowered ALT (alanine aminotransferase, a liver enzyme that rises with liver stress) and GGT (gamma-glutamyl transferase, another liver-stress enzyme) but did not change liver fat, its primary endpoint, and showed no clear dose-response. Findings are conflicted because pterostilbene alone raised LDL cholesterol (low-density lipoprotein, the “bad” cholesterol) in a separate trial, so its net metabolic effect is uncertain.

Magnitude: Significant time-dependent reductions in ALT and GGT versus placebo at the standard dose; no change in the primary measure of liver fat (single RCT, n = 111).

Cognitive and Neuroprotective Effects

Pterostilbene protects neurons in animal models of aging, stroke, and neurodegeneration through its antioxidant and anti-inflammatory actions, and it crosses into brain tissue owing to its fat solubility. The evidence basis is almost entirely preclinical, with human neurological data limited to ongoing trials in amyotrophic lateral sclerosis (ALS, a progressive nerve-and-muscle disease) using a nicotinamide-riboside combination. No controlled human cognitive-outcome data exist yet.

Magnitude: Not quantified in available studies.

NAD+ and Cellular-Energy Support (with Nicotinamide Riboside) ⚠️ Conflicted

As the sirtuin-activating partner to nicotinamide riboside, pterostilbene is included in formulations shown to raise blood NAD+ levels, the coenzyme that fuels cellular energy and repair and declines with age. The evidence basis is several small RCTs (in acute kidney injury and healthy elderly adults) that reliably show NAD+ elevation and good safety; however, a trial testing the combination for muscle regeneration after injury found no functional benefit. The NAD+ rise is driven mainly by the nicotinamide riboside component, making pterostilbene’s independent contribution hard to isolate.

Magnitude: Blood NAD+ increases of roughly 37–90% with the nicotinamide-riboside/pterostilbene combination; no measurable improvement in muscle recovery in the injury trial (RCTs, n = 24 and n = 32).

Speculative 🟨

Lifespan and Healthspan Extension (Caloric-Restriction Mimicry)

Pterostilbene extends mean lifespan in fruit flies and improves several aging markers in rodents, apparently by engaging the same sirtuin, AMPK, and mTOR pathways that respond to eating less. Because no controlled human longevity data exist, the basis is mechanistic and animal-model only; the framing as a “calorie-restriction mimic” is a hypothesis extrapolated from short-lived organisms.

Anticancer and Chemopreventive Potential

Across many cell and animal cancer models, pterostilbene slows proliferation and promotes cancer-cell death through multiple signaling pathways. The basis is preclinical, supported only by a single early-phase human trial in endometrial pre-cancer that is still underway; no efficacy outcomes in people are available, so any anticancer claim is speculative.

Benefit-Modifying Factors

Genetic polymorphisms: Variation in UGT and SULT enzymes (which attach clearance tags to pterostilbene) can alter how quickly it is metabolized and therefore how much reaches tissues, potentially shifting the dose needed for an effect. Sirtuin-pathway gene variants may also modify responsiveness, though this is not yet characterized in humans.
Baseline biomarker levels: People starting with elevated blood pressure, higher oxidative-stress or inflammatory markers, or raised liver enzymes have the most measurable room to improve; those already optimized may see little change.
Sex-based differences: Animal lifespan data suggest the compound can act through different protein targets in males and females, and human trials to date have been small and often male-skewed, leaving true sex differences in benefit largely unknown.
Pre-existing conditions: Metabolic syndrome, fatty liver, or elevated blood pressure define the populations most likely to see benefit; conversely, existing dyslipidemia (abnormal blood fats) may make the LDL-raising signal more relevant.
Age: Because NAD+ and sirtuin activity decline with age, older adults at the upper end of the target range are hypothesized to benefit more from sirtuin-supporting strategies, but this remains unproven for pterostilbene specifically.

Potential Risks & Side Effects

A dedicated search of the human trial literature and drug-reference sources was performed. Pterostilbene has a favorable short-term safety record; the main documented concern is an effect on cholesterol. Content is framed for a proactive adult, not for the average patient.

Medium 🟥 🟥

LDL Cholesterol Elevation ⚠️ Conflicted

In the pivotal cardiometabolic RCT, pterostilbene taken on its own raised LDL cholesterol and total cholesterol, an unexpected and clinically relevant signal given that cholesterol was the trial’s focus. The evidence basis is that same 80-person RCT; the effect appeared with pterostilbene monotherapy and was attenuated when it was combined with a grape-derived extract, which is why it is flagged as conflicted. The mechanism is unclear and the finding has not been reproduced in a dedicated lipid trial, but it is the single most important reason to monitor a lipid panel.

Magnitude: Statistically significant increases in LDL and total cholesterol with pterostilbene monotherapy over 6–8 weeks; effect blunted by co-administered grape extract (single RCT, n = 80).

Low 🟥

Gastrointestinal Discomfort

Mild digestive upset — nausea, loose stools, or abdominal discomfort — is the most commonly reported day-to-day side effect, generally at higher doses and often in combination products. The basis is scattered reports within small RCTs, where a minority of participants noted minor gastrointestinal effects that did not require stopping. It is typically transient and dose-related.

Magnitude: Minor gastrointestinal complaints in roughly 3 of 20 treated participants in a dose-escalation safety trial.

Additive Blood-Pressure Lowering

Because pterostilbene can lower blood pressure, combining it with other blood-pressure-lowering agents or supplements could push readings too low in susceptible individuals. The basis is the demonstrated blood-pressure effect in the human trial extrapolated to a plausible additive interaction; no case reports of harmful hypotension (abnormally low blood pressure) specifically from pterostilbene are documented. Practically relevant mainly for people already on antihypertensive therapy.

Magnitude: Not quantified in available studies.

Speculative 🟨

Drug-Metabolism Interactions

By occupying UGT and SULT conjugation enzymes, pterostilbene could in theory alter the clearance of medications cleared by the same routes, changing their blood levels. The basis is mechanistic and from laboratory studies rather than documented human interactions, so the real-world magnitude is unknown.

Theoretical Hormonal Activity

As a stilbene structurally distant relative of plant estrogens, pterostilbene has been examined for weak hormone-receptor activity, raising a theoretical question for hormone-sensitive conditions. Evidence is limited to isolated cell studies showing minimal estrogenic effect; there are no human signals, making this a low-probability, speculative concern.

Risk-Modifying Factors

Genetic polymorphisms: Reduced-function UGT or SULT variants could slow pterostilbene clearance, raising exposure and the chance of dose-related side effects or metabolism-based interactions.
Baseline biomarker levels: Individuals with already-elevated LDL cholesterol are the group for whom the cholesterol-raising signal matters most, warranting closer lipid monitoring.
Sex-based differences: Human safety data are dominated by small, often male-heavy trials, so sex-specific risk patterns — including any hormonal effects — are not well defined.
Pre-existing conditions: Established cardiovascular disease or dyslipidemia raises the stakes of an adverse lipid change; low baseline blood pressure raises the relevance of the blood-pressure-lowering effect.
Age: Older adults are more likely to be taking multiple medications, increasing the practical importance of the theoretical drug-metabolism interactions, and may be more sensitive to blood-pressure changes.

Key Interactions & Contraindications

Prescription drugs: Antihypertensives (blood-pressure medications such as amlodipine, lisinopril, losartan) — caution, monitor; additive effect may cause excessive blood-pressure lowering, so watch for dizziness. Anticoagulants and antiplatelet drugs (e.g., warfarin, clopidogrel) — caution; stilbenes can mildly affect platelet function, theoretically increasing bleeding risk.
Over-the-counter medications: Nonsteroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen) — monitor; overlapping effects on inflammatory signaling and any platelet effect are of low concern but worth noting. Acetaminophen — caution in high-dose combination, as both undergo liver conjugation.
Supplement interactions: Other blood-pressure-lowering supplements (e.g., magnesium, potassium, garlic extract, CoQ10) — additive blood-pressure effect; monitor. Resveratrol — overlapping pathways and conjugation routes; effects may be redundant rather than strictly additive.
Additive-effect supplements: Nicotinamide riboside and nicotinamide mononucleotide (NAD+ precursors) are intentionally combined with pterostilbene to jointly support the sirtuin–NAD+ system; this pairing is the basis of leading commercial products rather than a hazard.
Other interventions: Calorie restriction and fasting engage the same AMPK/sirtuin/mTOR pathways, so effects may overlap; this is generally considered complementary.
Populations who should avoid or use caution: Pregnant or breastfeeding individuals (no safety data); people with hormone-sensitive conditions given the unresolved theoretical estrogenic question; those with existing high LDL cholesterol until a lipid panel is checked; anyone scheduled for surgery within the next 1–2 weeks (stop in advance because of the theoretical platelet effect); and people on multiple medications cleared by conjugation enzymes.

Risk Mitigation Strategies

Baseline and follow-up lipid testing: Because the clearest documented risk is an LDL and total-cholesterol increase, check a full lipid panel before starting and again at 8–12 weeks; discontinue if LDL rises meaningfully, to prevent an adverse cardiovascular shift.
Start low and reassess: Begin at a modest dose (e.g., 50 mg/day) and only increase toward 250 mg/day after confirming tolerance, which limits both gastrointestinal upset and any exaggerated blood-pressure drop.
Blood-pressure self-monitoring: For anyone on antihypertensives or other pressure-lowering supplements, track home blood pressure during the first month to catch excessive lowering (dizziness, lightheadedness) early.
Separate from conjugation-dependent drugs: Where a medication is known to be cleared by glucuronidation or sulfation, separate dosing timing and monitor that drug’s effect, mitigating the theoretical metabolism interaction.
Pause before surgery: Stop pterostilbene 1–2 weeks before any planned procedure to neutralize the theoretical bleeding-risk contribution.
Prefer tested single-ingredient or reputable combination products: Using third-party-tested products at labeled doses reduces the risk of contaminants or mislabeled potency that could amplify side effects.

Therapeutic Protocol

Standard dose range: Practitioners in the longevity space typically use 50–250 mg/day. The 250 mg/day level (often split as 125 mg twice daily) is the dose studied in the main human cardiometabolic trial; lower doses (50 mg) are common in nicotinamide-riboside combination products.
Competing approaches: Two main patterns exist without one being the default — (a) pterostilbene alone at 100–250 mg/day, favored by those targeting blood pressure or antioxidant effects, and (b) pterostilbene at ~50 mg paired with ~250–500 mg nicotinamide riboside, the approach popularized by the commercial NAD+-restoration formulation developed with sirtuin researcher Leonard Guarente.
Who popularized each: The standalone metabolic approach traces to the University of Mississippi trial protocol; the combination approach was popularized by Elysium Health’s Basis product and the associated academic collaborators.
Best time of day: It is generally taken with a meal containing fat to aid absorption; morning dosing is common, and there is no strong evidence favoring night dosing.
Half-life: The compound’s short elimination half-life (roughly 1–2 hours) means blood levels do not persist long, which is part of the rationale for split dosing.
Single versus split dosing: Twice-daily dosing (matching the main RCT) is used to maintain more consistent exposure given the short half-life; once-daily dosing is common in convenience-oriented combination products.
Genetic considerations: UGT/SULT metabolizer status may in principle influence the effective dose, but no pharmacogenetic dosing guidance is validated; APOE (a gene affecting lipid transport and linked to Alzheimer’s-disease risk) and other longevity-linked variants have not been tied to pterostilbene response.
Sex-based differences: No sex-specific dosing is established; trials have been too small and male-weighted to define one.
Age considerations: Older adults are the primary users given age-related NAD+ decline, but no age-adjusted dose is validated; starting low is prudent.
Baseline biomarkers: Baseline blood pressure, lipids, and liver enzymes help define who is most likely to benefit and who needs closest monitoring.
Pre-existing conditions: People with dyslipidemia or on antihypertensives should individualize the decision to start and the monitoring cadence.

Discontinuation & Cycling

Lifelong versus short-term: Pterostilbene is generally used as an open-ended daily supplement rather than a defined course; there is no established treatment duration, and human trials have run only weeks to months.
Withdrawal effects: No withdrawal syndrome or rebound effect has been documented; because its half-life is short, the compound clears from the body within roughly a day of stopping.
Tapering: No taper is required; it can be stopped abruptly without known adverse consequences.
Cycling: Whether cycling preserves benefit is unknown. Some users cycle sirtuin-activating compounds (e.g., several weeks on, one week off) on the theoretical grounds of avoiding pathway adaptation, but there is no human evidence that cycling improves or is needed to maintain efficacy.
Practical discontinuation trigger: The most concrete reason to stop is an unfavorable lipid change on follow-up testing, after which markers would be expected to normalize.

Sourcing and Quality

Purity and form: Look for products specifying trans-pterostilbene (the active geometric form) at stated purity, ideally ≥98%; the branded pTeroPure ingredient is a well-characterized synthetic form used in much of the research.
Third-party testing: Choose products with independent verification (e.g., NSF, USP, or a published certificate of analysis) to confirm identity, potency, and absence of contaminants, since supplement labels are not pre-approved by regulators.
Reputable sources: Established longevity-supplement brands and the combination products built around the pTeroPure ingredient (including the Elysium and Life Extension lines) are commonly used; single-ingredient capsules from third-party-tested brands are also widely available.
Formulation notes: Newer cocrystal formulations are being developed to further improve absorption; because pterostilbene is fat-soluble, taking it with food containing fat can aid uptake regardless of brand.

Practical Considerations

Time to effect: Biomarker changes such as blood pressure emerged over 6–8 weeks in the human trial; antioxidant and metabolic effects are not immediately perceptible, so a 2–3 month trial with before-and-after labs is a reasonable evaluation window.
Common pitfalls: Expecting resveratrol-like “anti-aging” results from human data that do not yet exist; overlooking the LDL-cholesterol signal by not checking lipids; and assuming benefits attributed to the nicotinamide-riboside combination come from pterostilbene alone.
Regulatory status: In the United States it is sold as a dietary supplement, not a drug; it is not approved to treat any disease, and marketing claims are limited to structure/function statements. It is not a controlled or prescription substance.
Cost and accessibility: It is inexpensive and widely available online and in supplement retailers; standalone pterostilbene is generally low-cost, while branded NAD+ combination products are considerably more expensive.

Interaction with Foundational Habits

Sleep: Indirect and largely neutral. There is no evidence pterostilbene disrupts sleep, and its short half-life means evening dosing is unlikely to interfere; any sleep benefit would be secondary to reduced inflammation rather than a direct effect. Practically, timing can be set for convenience.
Nutrition: Direct and potentiating on absorption. As a fat-soluble compound, uptake improves when taken with a fat-containing meal. Its own dietary sources (blueberries, grapes) are modest, so supplementation rather than diet drives meaningful intake; a polyphenol-rich diet is broadly complementary.
Exercise: Indirect and potentially complementary. Pterostilbene’s AMPK activation overlaps with exercise-induced signaling, and it is being studied around exercise-induced oxidative stress; there is no evidence it blunts training adaptations, and no specific timing around workouts is established.
Stress management: Indirect. By dampening NF-κB-driven inflammation and oxidative stress, it may buffer some downstream effects of chronic stress, but it does not directly modulate cortisol or the stress response, and it is not a substitute for behavioral stress management.

Monitoring Protocol & Defining Success

Baseline testing should be done before starting to characterize cardiovascular and liver status and to catch anyone for whom the cholesterol signal is a concern. Ongoing monitoring is light but should specifically recheck lipids.

Suggested cadence: baseline before starting, a first recheck at 8–12 weeks (especially the lipid panel and blood pressure), and thereafter every 6–12 months if continued long-term.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Blood pressure	<120/80 mmHg	Tracks the main documented benefit and guards against excessive lowering	Use home readings over several days; recheck at 4–8 weeks; more relevant if on antihypertensives
LDL cholesterol (LDL-C)	<100 mg/dL (lower if high cardiovascular risk)	Detects the key documented risk (LDL elevation)	Fasting panel; conventional labs may call up to 130 mg/dL “normal,” but functional targets are lower; recheck at 8–12 weeks
Total cholesterol & full lipid panel	Total <180–200 mg/dL; HDL >50 mg/dL	Contextualizes any LDL change and overall lipid balance	Fasting; pair with LDL-C; HDL is the “good” cholesterol
ALT & GGT (liver enzymes)	ALT <25 U/L (functional); GGT <25 U/L	Monitors liver safety and the combination-product benefit signal	Conventional upper limits (~40–55 U/L) are looser than functional targets; best fasting
Fasting glucose & HbA1c	Glucose 75–90 mg/dL; HbA1c <5.4%	Screens the metabolic effects seen in animal and combination studies	HbA1c reflects ~3-month average glucose; fasting sample for glucose
hs-CRP	<1.0 mg/L	Captures the anti-inflammatory effect on a general inflammation marker	High-sensitivity C-reactive protein; avoid testing during acute illness, which transiently raises it
eGFR & creatinine (kidney function)	eGFR >90 mL/min/1.73m²	Baseline safety context, relevant to combination-product research in kidney injury	Estimated glomerular filtration rate is calculated from creatinine; hydration affects readings

Qualitative markers to track alongside labs:

Energy levels and daytime alertness
Exercise tolerance and recovery
Cognitive clarity and focus
General sense of well-being and absence of digestive upset

Emerging Research

Research is moving in directions that could either strengthen the case (neurodegeneration and healthspan trials) or weaken it (null functional outcomes and the unresolved lipid signal). Findings are framed for a proactive adult evaluating a still-maturing evidence base.

Neurodegeneration (ALS): The NO-ALS trial (NCT04562831) is testing a nicotinamide/pterostilbene supplement in amyotrophic lateral sclerosis, enrolling 380 participants with disease progression (ALS Functional Rating Scale) as the primary endpoint — one of the largest human tests of this combination.
Combination longevity/healthspan: The Combination Gerotherapeutic Interventions for Healthspan trial (NCT07475546) combines pterostilbene with other candidate longevity agents in 30 adults, measuring aerobic fitness, cognition, an inflammation index, and lean body mass — directly relevant to the healthspan question.
Cancer prevention: The endometrial cancer trial (NCT03671811) tests megestrol acetate with or without pterostilbene in 44 patients, using a tumor cell-proliferation marker as its primary outcome — the first controlled human read on the anticancer signal.
Bioavailability engineering: The completed BIOPTERO2 cocrystal study (NCT06289140) compared a new pterostilbene cocrystal formulation against the free form for absorption, reflecting active work to make dosing more efficient.
Metabolic/liver evidence: The published NAFLD trial, Dellinger et al., 2023, reported reduced liver-inflammation markers with the nicotinamide-riboside/pterostilbene combination but no change in liver fat, illustrating both the promise and the limits of current human data.
Future directions (mechanism and oncology): A recent overview, Ali et al., 2025, maps the anticancer mechanisms and argues that dedicated human efficacy trials — not more preclinical work — are the key missing piece; adequately powered lipid and cardiovascular-outcome trials remain the other major gap that could change current understanding.

Conclusion

Pterostilbene is a natural compound closely related to resveratrol but absorbed far more efficiently, which is the main reason it has attracted attention among people interested in healthy aging. It appears to switch on cellular repair and antioxidant systems similar to those triggered by eating less, and much of its use pairs it with a vitamin-based cellular-energy booster.

The strongest human finding is a modest lowering of blood pressure in a single small trial, alongside reductions in oxidative stress and, in combination products, in markers of liver inflammation. Balanced against this, the same key trial found that pterostilbene on its own raised “bad” cholesterol, and a study of muscle recovery showed no benefit — so the picture is mixed and rests on very few human studies. Most of the excitement about longevity and anticancer effects comes from cell and animal research that has not yet been confirmed in people.

Short-term use appears safe and well tolerated, with mild digestive upset the most common complaint and the cholesterol change the most important thing to watch. Overall, pterostilbene sits in a promising but early stage: mechanistically compelling, lightly supported by human evidence, and genuinely uncertain where its animal-model benefits will translate.

Top - Benefits - Risks - Protocol

Pterostilbene for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Blood Pressure Reduction

Reduction of Oxidative Stress and Inflammation

Low 🟩

Metabolic and Liver Support (with Nicotinamide Riboside) ⚠️ Conflicted

Cognitive and Neuroprotective Effects

NAD+ and Cellular-Energy Support (with Nicotinamide Riboside) ⚠️ Conflicted

Speculative 🟨

Lifespan and Healthspan Extension (Caloric-Restriction Mimicry)

Anticancer and Chemopreventive Potential

Benefit-Modifying Factors

Potential Risks & Side Effects

Medium 🟥 🟥

LDL Cholesterol Elevation ⚠️ Conflicted

Low 🟥

Gastrointestinal Discomfort

Additive Blood-Pressure Lowering

Speculative 🟨

Drug-Metabolism Interactions

Theoretical Hormonal Activity

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion